We are Fulfilling Unmet Needs in Pulmonary Medicine.

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.

Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:

• Continued development of proprietary respiratory disease therapies

• Pursue regulatory pathways that reduce the time, costs and risks associated with product development

• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing

• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States

• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise

News & Events

Aradigm to Host Corporate Update Conference Call on June 26
[25JUN14]

Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
[24JUN14]

On May 23, 2014, the Company effected the reverse split of all outstanding Common Stock approved by shareholders on April 18, 2014. The split ratio is 40 to 1. The temporary trading symbol of Aradigm Common Stock is ARDMD. The Company’s Form 8937 contains more information concerning this organizational action and its effect on the tax basis of the securities.
[27MAY14]

More News >>